CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
CIK cells +4 moredrug
Likely dose
Cyclosporine 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01392989
NCT01392989Phase 2Completed
CompareCT.gov

Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders

Everett Meyer·interventional·Posted Jul 13, 2011·Updated May 7, 2019

In Brief

A Phase 2 clinical trial evaluating CIK cells, Cyclosporine, and 3 other interventions for Neural Tube Defects and 5 related conditions. Completed, enrolled 44 participants across 1 site.

Detailed Summary

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2011
Enrollment StartMar 1, 2011
Primary CompletionJun 7, 2016
Study CompletionMar 19, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 15.0 years ago

Interventions

CIK cellsdrug

Standard of care

Cyclosporinedrug

5 mg/kg, po

Mycophenolate Mofetildrug

15 mg/kg, oral

Thymoglobulindrug

7.5 mg/kg, IV

Total Lymphoid Irradiation (TLI)radiation